Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review.

**CURRENT STATUS:** UNDER REVIEW

*Health and Quality of Life Outcomes*  ▶ *BMC*

Gian Loreto D’Alò  
Department of Epidemiology, Lazio Regional Health Service  
*ORCiD:* [https://orcid.org/0000-0002-4125-2066](https://orcid.org/0000-0002-4125-2066)

Franco De Crescenzo  
✉ [f.decrescenzo@deplazio.it](mailto:f.decrescenzo@deplazio.it)  
*Corresponding Author*  
*ORCiD:* [https://orcid.org/0000-0002-2478-7763](https://orcid.org/0000-0002-2478-7763)

Laura Amato  
Regione Lazio

Fabio Cruciani  
Regione Lazio

Marina Davoli  
Regione Lazio

Francesca Fulceri  
Istituto Superiore Di Sanita

Silvia Minozzi  
Regione Lazio

Zuzana Mitrova  
Regione Lazio

Gian Paolo Morgano  
McMaster University

Franco Nardocci  
Istituto Superiore Di Sanita

Rosella Saulle
Regione Lazio

Holger Jens Schünemann
McMaster University

Maria Luisa Scattoni
Istituto Superiore Di Sanita

DOI:
10.21203/rs.2.21903/v1

SUBJECT AREAS
Health Economics & Outcomes Research

KEYWORDS
Autism Spectrum Disorder, Antipsychotic Agents, Systematic Review, Guideline, GRADE Approach.
Abstract
Background: It is unclear whether the administration of antipsychotics to children and adolescents with autism spectrum disorders (ASD) is acceptable, equitable, and feasible.

Methods: We performed a systematic review to support a multidisciplinary panel in formulating a recommendation on antipsychotics, for the development of the Italian national guidelines for the management of ASD. A comprehensive search strategy was performed to find data related to intervention acceptability, health equity, and implementation feasibility. We used quantitative data from randomized controlled trials to perform a meta-analysis assessing the acceptability and tolerability of antipsychotics, and we estimated the certainty of the effect according to the GRADE approach. We extracted data from systematic reviews, primary studies, and grey literature, and we assessed the risk of bias and methodological quality of the published studies.

Results: Antipsychotics were acceptable (dropouts due to any cause: RR 0.61, 95% CI 0.48-0.78, moderate certainty of evidence) and well tolerated (dropouts due to adverse events: RR 0.99, 95% CI 0.55-1.79, low certainty of evidence) by children and adolescents with ASD. Parents and clinicians did not raise significant issues concerning acceptability. We did not find studies reporting evidence of reduced equity for antipsychotics in disadvantaged subgroups of children and adolescents with ASD. Workloads, cost barriers, and inadequate monitoring of metabolic adverse events were indirect evidence of concerns for feasibility.

Conclusion: Antipsychotics in children and adolescents with ASD were likely acceptable and possibly feasible. We did not find evidence of concern for equity.

Introduction
Autism spectrum disorder (ASD) is an early onset, neurodevelopmental disorder that causes a broad set of socio-communication deficits and restricted or repetitive behaviors. ASD is commonly associated with problem behaviors such as hyperactivity, irritability, and self-harm [1, 2]. ASD symptomatology causes reduced functioning, regardless of intellectual ability [3, 4]. The prevalence of ASD worldwide is about 1–2% [5], while in Italy, it is 1.14%-1.3% [6, 7], with a male: female ratio of about 4:1. About 48% of children with ASD are affected by a form of intellectual disability [8, 9]. The
costs of ASD are enormous for both families and society. In the United Kingdom and the USA, the estimated lifelong costs to support an individual with ASD range between 1.2 to 2 million euros, depending on the presence of intellectual disability [10].

Irritability and aggression are treatment targets for the use of antipsychotics in ASD [11]. The food and drug administration (FDA) approved risperidone and aripiprazole for the treatment of irritability in ASD, while no pharmacological treatment proved to be effective in treating core symptoms [12].

It is not apparent whether antipsychotics are acceptable and feasible to a population of children and adolescents with ASD. Parents could be reluctant to administer antipsychotics to their children, and concern towards adverse events often leads parents to prefer complementary and alternative medicines [12, 13]. Adverse events related to antipsychotics, such as increased appetite, weight gain, diabetes mellitus, and hyperlipidemia [14, 15], may also discourage clinicians from prescribing them in children and adolescents with ASD. Adverse events can as well lead to treatment discontinuation and switch to other drugs. Furthermore, children with ASD often display difficulties with swallowing tablet-form and liquid-form medications [16], and these difficulties are increased among individuals with developmental disabilities. Parents often have to manage pill-swallowing difficulties on their own; they often use some form of coercion to achieve immediate compliance, but such behavior could lead children to develop anxiety, aversion to pills, and increased food selectivity [17].

In this study, we aimed to systematically review the evidence on acceptability, equity and feasibility of antipsychotics in children and adolescents with ASD.

Methods
Context
The Italian National Institute of Health (in Italian: Istituto Superiore di Sanità – ISS) is currently developing evidence-based guidelines for the diagnosis and treatment of ASD in children and adolescents. Equity, acceptability, and feasibility are contextual factors that influence recommendations developing using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision framework. We conducted this systematic review to support the ISS autism guidelines panel in formulating a recommendation on the use of antipsychotics,
according to the ISS manual [18]. This project was carried out in conjunction with a multidisciplinary panel, which included subject experts, people with ASD, and their caregivers.

The questions
We addressed the following clinically and public health relevant questions on the use of antipsychotics for children and adolescents with ASD:

What would be the impact of antipsychotics on health equity?
Are antipsychotics acceptable to key stakeholders?
Are antipsychotics feasible to implement?

Population
Children and adolescents aged 0–18 years, of both genders, with a primary diagnosis of autism spectrum disorder.

Intervention
Antipsychotics selected by Guidelines panel members, including aripiprazole, clozapine, haloperidol, levosulpiride, lurasidone, olanzapine, risperidone and trifluoperazine.

Outcomes
Equity, defined as the presence of plausible reasons for anticipating differences in the relative effectiveness of the intervention for disadvantaged subgroups or different baseline conditions across disadvantaged subgroups that affect the absolute effectiveness of the intervention or the importance of the problem [19, 20].

Acceptability, defined as the likelihood for the key stakeholders to accept or agree with:
- the distribution of the benefits, harms, and costs;
- the costs or undesirable effects in the short term, for desirable effects (benefits) in the future;
- the values attached to the desirable or undesirable effect [19];
- discontinuation due to any cause, as measured in randomized controlled trials (RCT) and compared versus placebo.

Feasibility, defined as sustainability of the intervention and the capability to address potential barriers to using it [19].

Types of studies included
For each considered domain, we included systematic review, observational, and experimental studies.

Literature search
The literature search was conducted up to January 2019. No language filters were applied. We searched Central, Medline, Embase, Web of Science, and PsycInfo. The search strategies are reported
in Additional file 1.

**Study selection and data extraction**

Two reviewers (GLD, FDC) independently screened titles and abstracts of the publications obtained by the search strategies. The same authors independently assessed the inclusion of the full text of studies that potentially satisfied inclusion criteria. Disagreements were resolved by a consensus meeting or by a third reviewer (LA).

Two reviewers (GLD, FDC) independently extracted data. The full methodology followed for extracting data for each considered domain is in Additional file 2 [19, 21, 22].

**Data analysis and synthesis**

Quantitative data extracted from RCTs (discontinuation due to any cause and discontinuation due to adverse event) were analyzed by the Risk Ratio (RR) using a random effect model [23] and expressing uncertainty with its 95% confidence interval (CI). Heterogeneity between studies was explored by the I-squared statistic and by visual inspection of the forest plots. For the two outcomes, we produced a summary of findings table based on the methodology developed from the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group [19, 24, 25, 26, 27]. We assigned four levels of certainty in the evidence: high, moderate, low, very low, based on different ratings on study limitations, indirectness, inconsistency, imprecision of effect estimates, and risk of publication bias. The results were accompanied by a narrative statement, as advised by Santesso et al. (2019) [28].

We synthetized narratively data retrieved from systematic reviews and observational studies on acceptability, feasibility and equity of antipsychotics in children and adolescents with ASD.

We used the GRADE Evidence to Decision (EtD) framework criteria to present and summarize the results.

**Quality assessment**

For RCTs, we used the Cochrane tool for risk of bias assessment [29], assessing: sequence generation; allocation concealment; blinding of participants, providers and outcome assessors; incomplete outcome data; selective reporting. A 'Risk of bias' table was created for the included studies, indicating the study's performance in each of the domains mentioned above, in terms of low,
high, or unclear risk of bias. We used the Newcastle Ottawa Scale (NOS) for the quality assessment of case-control and cohort studies [30], and a modified version of NOS [31] for cross-sectional studies. To assess the methodological quality of the systematic reviews and meta-analyses included in our study, we used Amstar 2 [32].

Main Text
Search strategy results
Through bibliographic searches, we identified 1388 reports after removing duplicates; we excluded 1266 studies on the basis of title and abstract. We retrieved 122 articles in full text for more detailed evaluation, 80 of which we excluded after reading the full text; of the remaining 42 studies, 35 were primary or secondary references referring to 15 RCTs [33-47], 6 were observational studies [48-53], and 1 was a systematic review [54]. See Figure 1 for the flow chart, and Additional file 3 for the full references for included and excluded studies. We reported the methodological quality of included studies in Additional file 4, Additional file 5 and Additional file 6.

Equity
We did not find any study that reported data concerning equity in the use of antipsychotics in children and adolescents with ASD.

Acceptability
Acceptability by parents
Bowker et al. (2011) [48] carried out an online survey to investigate the motivations behind the therapeutic choice of parents of children and adolescents with ASD and their perception of the changes following the therapy undertaken. 970 questionnaires were collected (93% from North America), 96.4% from children and adolescents with ASD, and completed by parents. The survey showed that 77% of subjects had received therapy for ASD during their lifetime, but only 14.6% were on medication at the time the study was conducted. According to the parent's judgment of the effectiveness of the treatment, the area of functioning that benefited most from drug therapy was behavioral (31.9%). In contrast, a smaller number of parents indicated more notable benefits in the cognitive (16.3%), attention (14.2%), linguistic (12.8%), social (11.3%), and physical (3.5%) areas. Drug therapy was
discontinued by 20% of the population. The reasons for discontinuation were mainly lack of efficacy (43% in total and 17% among those who had used antipsychotics at least once) and adverse events (29% in total and 11% among those who had used drug therapy at least once).

The same study reported some factors that parents considered determinant in choosing the type of treatment for their children with ASD, including:

1. a) opinions about the causes of the disorder;
2. b) parental style;
3. c) lifestyle;
4. d) socio-economic status;
5. e) ease of access to services and care;
6. f) impact of the media and the testimonies of other families.

The study concluded that the scientific evidence is not, for parents, decisive for the choice of treatments. Therapies supported by evidence are often underused, while frequently, non-evidence-based treatments are used. Non-evidence-based treatments can be potentially harmful, and the scientific community has a responsibility to explore all possible avenues to help parents to make well-informed decisions.

A survey [50] (n = 96 questionnaires administered), performed in the context of an RCT on the administration of risperidone versus placebo, found the following significant correlations between parent satisfaction and demographic characteristics: a) low income to poor satisfaction with the number of visits (p = 0.003); b) the child's IQ ≥45 and white ethnicity with poor satisfaction to the learning tests (p = 0.043); c) the lower education to poor satisfaction with the behavioral assessment (P = 0.033).

**Acceptability by children and adolescent with ASD**

We found information on discontinuation due to any cause in 15 RCTs [33-47], and data on discontinuation due to adverse events in 12 RCTs [34-41,44-47]. We evaluated the risk of bias for the included RCTs ([Additional file 4](#)). We show forest plots of selected outcomes in [Figure 2, Figure 3](#).
Based on visual inspection of funnel plots, we considered that publication bias was not likely (Additional file 7). Results of meta-analyses and certainty of evidence in effect sizes are reported in Table 1.

Table 1: Summary of Findings for the comparison antipsychotics versus no antipsychotics:

| Outcomes                                      | Antipsychotics versus no Antipsychotics for children and adolescents with ASD | Patient or Population: children and adolescents with ASD | Setting: Inpatients and Outpatients | Intervention: Antipsychotics | Control: no Antipsychotics | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | No of participants (studies) | Certainty of the evidence (GRADE) | Comments |
|-----------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------|--------------------------------|-------------------------------|----------------------------------------|-----------------------------------|----------------------------------|-----------------------------------|----------|
| Discontinuation due to any cause (Follow up: median 8 weeks) | 244 per 1,000 (117 to 190)                                                   | RR 0.61 (0.48 to 0.78)                                    | 1124 (15 RCT)                     | MODERATE b                      | Antipsychotics probably reduce the risk of dropout due to any cause |
| Discontinuation due to adverse events (Follow up: median 8 weeks) | 39 per 1,000 (22 to 70)                                                     | RR 0.99 (0.55 to 1.79)                                    | 1010 (12 RCT)                     | LOW a,b                         | Antipsychotics may result in little to no difference in the risk of dropout due to adverse events |

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; SMD: Standardised mean difference; RR: Risk ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Explanations

1. Downgraded by one level because the 95% CI for SMD goes from considerable beneficial effects to undesirable effects.

2. Downgraded by one level because most studies showed an unclear risk for selection bias, four studies were at high risk for attrition bias, one study was at high risk for selection bias and one study was at high risk for reporting bias.
References

1. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry; 1978.

2. Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev; 2017.

3. Loebel A, Brams M, Goldman RS, Silva R, Hernandez D, Deng L, et al. Lurasidone for the treatment of irritability with autistic disorder. J Autism Dev Disord; 2016.

4. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry; 2009.

5. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med; 2002.

6. NCT00870727. Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders. clinicaltrial.gov; 2009.

7. Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders; 2013.

8. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol; 2006.

9. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro M, Zagursky K, Novotny
S., A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol; 2006.

10. NCT01624675, A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder. clinicaltrial.gov; 2012.

11. Findling RL, Mankoski R, Timko K, Learns K, McCartney T, McQuade RD, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry; 2014.

12. Nagaraj R, Singh P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol; 2006.

13. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics; 2004.

14. Remington G, Sloman L, Konstantareas M, Parker M, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol; 2001.

15. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009 Dec;124(6):1533-40. doi: 10.1542/peds.2008-3782.

Actual use of antipsychotics in children and adolescents with ASD and predictive factors of their use
Jobski et al. (2017) [54] carried out a systematic review on the use of psychotropic drugs in individuals with ASD, identifying 47 studies that referred to a total of more than 300,000 individuals. In 15 of the 35 studies included in the review, antipsychotics were the most widely administered drugs. About 46% of the children considered across studies were taking psychotropic drugs, with a median prevalence of antipsychotic use of 17%.

About polypharmacological therapy, 22% of the children were taking several psychiatric drugs at the same time; The use of psychopharmacological products increased with age. The authors hypothesized some underlying causes for explaining this phenomenon: a) the development, during growth, of problem behaviors accompanied by an increase in physical strength; b) less reluctance to administer drugs by doctors and parents; (c) having already exhausted attempts at alternative treatments such as behavioral therapies. In addition, the authors noted a trend to switch from stimulants to antipsychotics and antidepressants as age increased, and this trend was attributed to the decrease in symptoms typical of comorbid Attention Deficit/Hyperactivity Disorder, alongside the onset of other problem behaviors such as anxiety, aggression, and depression. Another study [49], conducted in the UK and not included in Jobski et al (2017) systematic review [54], enrolled a cohort of 3482 children and adolescents with ASD; according to the authors, about 10% of the included population was using antipsychotics, mainly risperidone (55%) and aripiprazole (32%), always associated with psychosocial therapy. The authors identified the following socio-demographic predictors of the use of antipsychotics: adolescent age (OR 1.11, 95% CI 1.05 to 1.16), low adaptive functioning inferred from the CGAS scale (OR 0.96, 95% CI 0.95 to 0.97), aggressive and self-harm behaviors (OR 1.85, 95% CI 1.30 to 2.63) and parental concern for symptoms (OR 2.02, 95% CI 1.27 to 3.22). Clinical predictors included hyperactivity (OR 1.44, 95% CI 1.01 to 2.06), depression (OR 2.36, 95% CI 1.37 to 4.09), obsessive-compulsive symptoms (OR 2.31, CI 95% from 1.16 to 4.61), tics (OR 2.76, CI 95% from 1.09 to 6.95), intellectual disability (OR 1.68, CI 95% from 1.11 to 2.53), and obviously psychosis (OR 5.71, CI 95% from 3.3 to 10.6).

Feasibility
In this section, we summarized barriers and facilitators to the implementation and sustainability of
antipsychotics administration using the findings from the three included studies [51-53]. We did not find studies that included children with ASD, but we found three studies considering children with intellectual disabilities and decided to use this evidence to inform this domain.

Among *facilitators*, the authors identified:

1) Nursing team. Nurses facilitate the monitoring of side effects and routine laboratory controls;
2) Electronic medical records. Electronic medical records are useful tools to assess treatment effects, monitor side effects, and facilitate communication between doctors;
3) Parental or caregiver support.

Among *barriers*, the authors identified:

1) Electronic medical records. Although perceived by some as facilitators, they are also considered a burden. There is no possibility to follow some parameters of treatment effects and side effects. When the system offers the possibility to monitor specific symptoms or effects of treatment, the possibilities are inflexible and time-consuming;
2) Workloads. The pressure and workloads experienced by health care professionals are barriers to the implementation of antipsychotics;
3) Cost barriers for the choice of drug (e.g. first-generation antipsychotics vs. second-generation antipsychotics);
4) Poor monitoring of metabolic adverse events of antipsychotics.

In **Table 2**, we summarized the results for all the considered EtD criteria.

**Table 2: Summary of Findings for each Evidence to Decision (EtD) framework criterion**
Antipsychotics were among the most prescribed drugs, with a median prevalence of use of 17% from stimulants to antipsychotics and anti-depressants as age increased was identified [49]. Socio-demographic predictors of the use of antipsychotics in our population: adolescent age, aggressive and self-harm behaviors, and parental concern for symptoms. Clinical predictors: depression, obsessive-compulsive symptoms, tics, intellectual disability, psychosis [49]. Drug therapy was the most frequently interrupted treatment (20%), mainly due to a lack of efficacy. Parents considered as crucial in choosing the treatment: opinions about the causes of the socio-economic status, ease of access to services and care, the impact of the media, and families, but not scientific evidence [48].

Low income, child’s IQ ≥45, lower parents’ education correlated to poor satisfaction with treatment, and behavioral assessment, respectively, in an RCT of risperidone vs. placebo [50].

Quantitative synthesis: antipsychotics in children and adolescents with ASD are acceptable (DO due to any cause: 15 RCTs [33-47], RR 0.61, 95% CI 0.48-0.78, moderate certainty of evidence) and well tolerated (DO due to AEs: 12 RCTs [34-41,44-47], RR 0.99, 95% CI 0.55-1.79, low certainty of evidence).

Feasibility

3 studies investigated the feasibility of administering antipsychotics to the general population [51-53].

Facilitators: Nursing team, Electronic medical records, Parental or caregiver support.

Barriers: Electronic medical records, workloads, Cost barriers for the choice of drug, inadequate monitoring of metabolic AEs.

Legend: AE: Adverse events; ASD: Autism Spectrum Disorder; DO: Dropout; EtD: Evidence to Decision; RCT: Randomized controlled trial;

Discussion

Antipsychotics are among the most widely prescribed drugs in children and adolescents with ASD, with a median prevalence of use of 17% [54]. This is in line with both the prevalence of irritability in this population, for which risperidone and aripiprazole are effective and indicated [12,55,56,57,58], and the frequent comorbidity with schizophrenia spectrum disorders symptoms [59].

On the basis of the available evidence, we found that antipsychotics were likely acceptable, and their implementation was potentially feasible. We did not find any information in the literature regarding the relation between antipsychotics administration and health equity. This could be because health disparities have not been observed, not expected, or not explored.

Parents reported the most frequent causes of drug discontinuation to be lack of efficacy and adverse events [48]. The higher rate of adverse events shown by recent meta-analyses [15,55] did not impact on discontinuation due to adverse events in our study. Moreover, according to a recent meta-analysis [60], antipsychotics had a reduced discontinuation due to lack of efficacy when compared against placebo. The reduced discontinuation may partially explain also the observed strong protective effect of the drugs on dropouts due to any cause.

We did not find any study focusing specifically on the feasibility of antipsychotics administration in children and adolescents with ASD. However, while no specific barriers seemed to arise from the
analysis of the acceptability, some concerns about the feasibility of proper monitoring of adverse
events remained when analyzing indirect evidence [51-53,61]. The implementation of facilitators
could help provide better monitoring and solve drug-related problems [51,53,61,62]. We found no
evidence for the equity.

Strengths and limitations
The conduct of evidence synthesis of contextual evidence that influences recommendations is an
emerging field in systematic review research, and we believe that our attempt to provide such
evidence is a strength. To inform each considered criterion of the EtD framework, we ran a
comprehensive search strategy to retrieve both randomized and non-randomized evidence. We also
performed a meta-analysis of randomized controlled trials to assess the acceptability and tolerability
of antipsychotics for children and adolescents with ASD. In our opinion, the combination of
quantitative and qualitative synthesis is an added study strength.

The use of the EtD framework in general, and the evaluation of its domains relating to equity,
acceptability and feasibility, requires the panel to be familiar with the tool [63], and this is a potential
limitation for the process of developing recommendations. To overcome this potential limitation,
about 2 months before the presentation of the body of evidence on antipsychotics, an EtD framework
on a pilot question was presented to the panel [64,65]. In other experiences, panel members have
reported that, when familiarity with the EtD framework is achieved, the tool helped them in
structuring discussion, saving time, ensuring systematicity in the process of recommendation
formulation [67].

We have not prospectively registered on PROSPERO or other databases the protocol for our
systematic review, and this is a study limitation. However, the clinical question was formulated by a
multidisciplinary panel of experts, and the methodology followed for the development of the
systematic review was based on the manual developed and published by the ISS [18].

Conclusions
Antipsychotics in children and adolescents with ASD were likely acceptable and possibly feasible. We
did not find evidence of concern for equity. Future clinical research needs to prioritize acceptable and
feasible interventions that contribute to reducing health inequities [68].

Abbreviations

**ASD**: Autism spectrum disorder; **D2**: Dopamine 2; **EtD**: Evidence to Decision; **GRADE**: grading of recommendations assessment, development and evaluation; **ISS**: Italian national institute of health; **NOS**: Newcastle Ottawa Scale; **PRISMA**: Preferred reporting items for systematic reviews and meta-analyses.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

All data supporting our findings is contained within the manuscript and the additional files.

The authors and can be contacted at f.decrescenzo@deplazio.it. (FDC) for further clarification, if required.

Competing interests

The authors declare that they have no competing interests.

Funding

Italian Ministry of Health Project ‘I disturbi dello spettro autistico: attività previste dal decreto ministeriale del 30.12.2016 – capitolo 4395 (articolo 1, comma 401, legge 28 dicembre 2015, n. 208, recante “Disposizioni per la formazione 661 del bilancio annuale e pluriennale dello Stato (legge di stabilità 2016)”.

Authors' contributions

Conceptualization: GLD, FDC, SM, GPM, HJS, LA.

Data curation: GLD, FDC, ZM, MD, LA.

Formal analysis: FDC, GLD, LA.

Project administration: MD, FN, HJS, LA, MLS.

Supervision: MLS, MD, FN, HJS, LA.

Writing – original draft: GLD, FDC, LA.
Acknowledgments

*Members of ISACA guideline working group*

Collaborating author names from the ISACA guideline working group: Raffaella, Tancredi; Angelo, Massagli; Giovanni, Valeri; Corrado, Cappa; Serafino, Buono; Giuseppe Maurizio, Arduino; Alessandro, Zuddas; Laura, Reali; Massimo, Molteni; Claudia, Felici; Concetta, Cordò; Lorella, Venturini; Cristina, Bellosio; Emanuela, Di Tommaso; Sandra, Biasci; Clelia M, Duff; Simona, Vecchi; Michele, Basile.

References

1. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: Author.

2. Farmer C, Thurm A, Grant P. Pharmacotherapy for the core symptoms in autistic disorder: current status of the research. Drugs. 2013;73(4):303-314. doi:10.1007/s40265-013-0021-7

3. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392(10146):508-520. doi: 10.1016/S0140-6736(18)31129-2.

4. Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest. 2008;118(1):6-14. doi: 10.1172/JCI32483.

5. Christensen DL, Braun KVN, Baio J, Bilder D, Charles J, Constantino JN, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ. 2018;65(13):1-23. doi:10.15585/mmwr.ss6513a1.

6. Narzisi A, Posada M, Barbieri F, Chericoni N, Ciuffolini D, Pinzino M. Prevalence of Autism Spectrum Disorder in a large Italian catchment area: a school-based population study within the ASDEU project. Epidemiol Psychiatr Sci. 2018;29:e5. doi:
10.1017/S2045796018000483.

7. Istituto Superiore di Sanità. Giornata mondiale della Consapevolezza dell’Autismo: in Italia un bimbo ogni 77. 2019. Available at: https://www.iss.it/?p=3421. Accessed: 31 Dec 2019.

8. Postorino V, Fatta LM, Sanges V, Giovagnoli G, De Peppo L, Vicari S, et al. Intellectual disability in Autism Spectrum Disorder: Investigation of prevalence in an Italian sample of children and adolescents. Res Dev Disabil. 2016 Jan;48:193-201. doi: 10.1016/j.ridd.2015.10.020.

9. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896-910.

10. Buescher AV, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721-8. doi: 10.1001/jamapediatrics.2014.210.

11. Park SY, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis SH, et al. Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2016;55(6):456-468.e4. doi: 10.1016/j.jaac.2016.03.012.

12. Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry. 2018;30(1):78-95. doi: 10.1080/09540261.2018.1458706.

13. DeFilippis M. The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder. Psychopharmacol Bull. 2018;48(1):40-63.

14. Krill RA, Kumra S. Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management. Adolesc Health Med Ther. 2014;5:171-182.
15. Alfageh BH, Wang Z, Mongkhon P, Besag FMC, Alhawassi TM, Brauer R, Wong ICK. Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Paediatr Drugs. 2019;21(3):153-167. doi: 10.1007/s40272-019-00333-x.

16. Schiff A, Tarbox J, Lanagan T, Farag P. Establishing compliance with liquid medication administration in a child with autism. J Appl Behav Anal. 2011;44(2):381-5.

17. Ghuman JK, Cataldo MD, Beck MH, Slifer KJ. Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(4):601-11.

18. Istituto Superiore di Sanità – Centro Nazionale per l’Eccellenza Clinica, la Qualità e la Sicurezza delle Cure. (ISS-CNEC) Manuale metodologico per la produzione di linee guida di pratica clinica. 2018. Available at: https://snlg.iss.it/wp-content/uploads/2018/10/MM_v1.2_lug-2018.pdf Accessed 17 Jan 2019.

19. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from: guidelinedevelopment.org/handbook. Accessed 16 Jan 2020.

20. Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 12. Incorporating considerations of equity. Health Res Policy Syst 2006;4:24.

21. O’Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. J Clin Epidemiol 2014;67:56e64.

22. Welch VA, Akl EA, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari MT, et al. GRADE equity guidelines 1: considering health equity in GRADE guideline development:
introduction and rationale. J Clin Epidemiol. 2017A;90:59-67.

23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177-88.

24. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.

25. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158-72.

26. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66(2):173-83.

27. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH, et al. Presenting results and “Summary of findings” tables. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008:335-8.

28. Santesso N, Glenton C, Dahm P, Garner P, Akl E, Alper B, et al.; GRADE Working Group. GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol. 2019 [Epub ahead of print]. doi: 10.1016/j.jclinepi.2019.10.014.

29. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.

30. Wells G, Shea B, O'connell DL, Peterson J, Welch V, Losos M, et al. (2014). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in
Meta-Analyses. Available at:
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed: 16 Jan 2020.

31. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al.; ESH Working Group on CV Risk in Low Resource Settings. Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601.

32. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi: 10.1136/bmj.j4008.

33. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1978;17(4):640-55.

34. Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry. 2014;75(1):22-30. doi:10.4088/JCP.13m08500.

35. Hollander E, Wasserman S, Swanson EN, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541-8. doi:10.1089/cap.2006.16.541.

36. Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev. 2017;48(5):796-806. doi: 10.1007/s10578-016-0704-x.
37. Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43(8):1773-83. doi: 10.1007/s10803-012-1723-5.

38. Loebel A, Brams M, Goldman RS, Silva R, Hernandez D, Deng L, et al. Lurasidone for the treatment of irritability with autistic disorder. J Autism Dev Disord. 2016;46:1153-63.

39. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575-87. doi:10.1089/cap.2006.16.575. PMI

40. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-9. doi: 10.1097/CHI.0b013e3181b76658.

41. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and behavioral problems. N Engl J Med. 2002;347(5):314-21. doi: 10.1056/NEJMoa013171 PMID: 12151468.

42. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-5. doi: 10.1177/08830738060210060801.

43. NCT00870727. Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders. First posted: 27th Mar 2009. Accessed: 18th Feb 2019.

44. NCT01624675. A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder. First posted: 21st Jun 2012. Accessed: 18th Feb 2019.
45. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-40. doi: 10.1542/peds.2008-3782.

46. Remington G, Sloman L, Konstantareas M, Parker M, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21(4):440-4.

47. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634-e41.

48. Bowker A, D'Angelo NM, Hicks R, Wells K. Treatments for autism: parental choices and perceptions of change. J Autism Dev Disord. 2011;41(10):1373-82. doi: 10.1007/s10803-010-1164-y.

49. Downs J, Hotopf M, Ford T, Simonoff E, Jackson RG, Shetty H, et al. Clinical predictors of antipsychotic use in children and adolescents with autism spectrum disorders: a historical open cohort study using electronic health records. Eur Child Adolesc Psychiatry. 2016;25(6):649-58. doi: 10.1007/s00787-015-0780-7.

50. Tierney E, Aman M, Stout D, Pappas K, Arnold LE, Vitiello B, et al. Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology (Berl). 2007;191(1):149-57.

51. Ramerman L, Hoekstra PJ, de Kuijper G. Exploring barriers and facilitators in the implementation and use of guideline recommendations on antipsychotic drug prescriptions for people with intellectual disability. J Appl Res Intellect Disabil. 2018;31(6):1062-1070. doi: 10.1111/jar.12461.

52. Rodday AM, Parsons SK, Mankiw C, Correll CU, Robb AS, Zima BT, et al. Child and adolescent psychiatrists' reported monitoring behaviors for second-generation
antipsychotics. J Child Adolesc Psychopharmacol. 2015;25(4):351-61. doi: 10.1089/cap.2014.0156.

53. Ronsley R, Raghuram K, Davidson J, Panagiotopoulos C. Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. J Can Acad Child Adolesc Psychiatry. 2011;20(2):134-41.

54. Jobski K, Höfer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand. 2017;135(1):8-28. doi: 10.1111/acps.12644.

55. Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. J Child Adolesc Psychopharmacol. 2019;29(3):168-180. doi: 10.1089/cap.2018.0115.

56. Lee ES., Vidal C, Findling RL. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. J Child Adolesc Psychopharmacol. 2018;28(9):582-605. doi: 10.1089/cap.2018.0037.

57. Fung LK, Mahajan R, Nozzolillo A, Bernal P, Krasner A, Jo B, et al. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics. 2016;137 Suppl 2:S124-35. doi: 10.1542/peds.2015-2851K.

58. Robb AS. Managing irritability and aggression in autism spectrum disorders in children and adolescents. Dev Disabil Res Rev. 2010;16(3):258-64. doi: 10.1002/ddrr.118.

59. De Giorgi R, De Crescenzo F, D’Alò GL, Rizzo Pesci N, Di Franco V, Sandini C, et al. Prevalence of Non-Affective Psychoses in Individuals with Autism Spectrum Disorders:
A Systematic Review. J Clin Med. 2019;8(9). doi: 10.3390/jcm8091304.

60. Pillay J, Boylan K, Carrey N, Newton A, Vandermeer B, Nuspl M, et al. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Mar. Available from http://www.ncbi.nlm.nih.gov/books/NBK442352/PubMed PMID: 28749632.

61. Javaheri KR, McLennan JD. Adherence to Antipsychotic Adverse Effect Monitoring Among a Referred Sample of Children with Intellectual Disabilities. J Child Adolesc Psychopharmacol. 2019;29(3):235-240. doi: 10.1089/cap.2018.0167.

62. Wongpakaran R, Suansanae T, Tan-Khum T, Kraivichian C, Ongarjsakulman R, Suthisisang C. Impact of providing psychiatry specialty pharmacist intervention on reducing drug-related problems among children with autism spectrum disorder related to disruptive behavioural symptoms: A prospective randomized open-label study. J Clin Pharm Ther. 2017;42(3):329-336. doi: 10.1111/jcpt.12518.

63. Moberg J, Oxman AD, Rosenbaum S, Schünemann HJ, Guyatt G, Flottorp S, et al.; GRADE Working Group. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018;16(1):45. doi: 10.1186/s12961-018-0320-2.

64. D’Alò GL, De Crescenzo F, Minozzi S, Morgano GP, Mitrova Z, Scattoni ML, et al. Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review. Submitted to Health Qual Life Outcomes.

65. De Crescenzo F, D’Alò GL, Morgano GP, Minozzi S, Mitrova Z, Saulle R, et al. Impact of polyunsaturated fatty acids on patient-important outcomes in children and adolescents with autism spectrum disorder: a systematic review. Submitted to Health
Qual Life Outcomes.

Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25. doi: 10.1016/j.jclinepi.2012.03.013.

Figures

Figure 1

Systematic review

| Study       | D2 blockers | Placebo |
|-------------|-------------|---------|
|             | Yes | No | Yes | No |
| Risperidone |     |    |     |    |
| Kent, 2013  | 11  | 50 | 8   | 27 |
| Luby, 2006  | 0   | 11 | 1   | 11 |
| McCracken, 2002 | 6   | 43 | 18  | 34 |
| Nasrallah 2005 | 0   | 10 | 1   | 20 |

| Risk Ratio | Weight |
|------------|--------|
|            | (%)    |
| RR [95% CI] |         |
| 0.79 [ 0.35, 1.77] | 8.68 |
| 0.36 [ 0.02, 8.04] | 0.59 |
| 0.35 [ 0.15, 0.82] | 8.13 |
| 0.27 [ 0.02, 8.01] | 0.58 |
Figure 2

Forest plots for discontinuation due to any cause

Random-effects DerSimonian-Laird model
| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Risperidone           |    |    |    |    | 1.74 [ 0.07, 41.64]    | 3.43       |
| Kent, 2013            | 1   | 60 | 0  | 35 | 0.36 [ 0.02, 8.04]     | 3.58       |
| Luby, 2006            | 0   | 11 | 1  | 11 | 0.35 [ 0.01, 8.47]     | 3.42       |
| McCracken, 2002       | 0   | 49 | 1  | 51 | 0.86 [ 0.02, 41.47]    | 2.30       |
| NCT01624675           | 0   | 21 | 0  | 18 | 0.95 [ 0.06, 14.69]    | 4.61       |
| Shea, 2004            | 1   | 40 | 1  | 38 | 0.71 [ 0.17, 2.92]     |            |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = 0.00\% \), \( H^2 = 1.00 \)
Test of \( H_0 : \tau^2 = 0 \); \( Q(4) = 0.73 \), \( p = 0.95 \)

Aripiprazole

| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Findling, 2014        | 0   | 41 | 1  | 43 | 0.36 [ 0.01, 8.53]     | 3.43       |
| Ichikawa, 2017        | 0   | 47 | 1  | 44 | 0.32 [ 0.01, 7.64]     | 3.42       |
| Marcus, 2009          | 17  | 149| 4  | 48 | 1.33 [ 0.47, 3.78]     | 31.68      |
| Owen, 2009            | 5   | 42 | 3  | 48 | 1.81 [ 0.46, 7.16]     | 18.24      |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = 0.00\% \), \( H^2 = 1.00 \)
Test of \( H_0 : \tau^2 = 0 \); \( Q(3) = 1.60 \), \( p = 0.66 \)

Olanzapine

| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Hollander, 2006       | 0   | 6  | 0  | 5  | 0.86 [ 0.02, 37.01]    | 2.43       |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = .\% \), \( H^2 = .\) .
Test of \( H_0 : \tau^2 = 0 \); \( Q(0) = 0.00 \), \( p = . \)

Lurasidone

| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Loebel, 2016          | 4   | 96 | 4  | 45 | 0.49 [ 0.13, 1.88]     | 19.13      |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = .\% \), \( H^2 = .\) .
Test of \( H_0 : \tau^2 = 0 \); \( Q(0) = 0.00 \), \( p = . \)

Haloperidol

| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Remington, 2001       | 3   | 8  | 0  | 7  | 4.67 [ 0.28, 78.68]    | 4.32       |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = .\% \), \( H^2 = .\) .
Test of \( H_0 : \tau^2 = 0 \); \( Q(0) = 0.00 \), \( p = . \)

Overall

| Study                  | D2 blockers | Placebo | Risk Ratio with 95% CI | Weight (%) |
|-----------------------|-------------|---------|------------------------|------------|
|                       | Yes | No | Yes | No |                        |            |
| Overall               |    |    |    |    | 0.99 [ 0.55, 1.79]     |            |

Heterogeneity: \( \tau^2 = 0.00 \), \( I^2 = 0.00\% \), \( H^2 = 1.00 \)
Test of \( H_0 : \tau^2 = 0 \); \( Q(11) = 5.08 \), \( p = 0.93 \)
Test of group differences: \( Q_r(4) = 2.78 \), \( p = 0.60 \)
Random-effects DerSimonian-Laird model

Figure 3

Forest plots for discontinuation due to adverse events
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Additional file 7.docx
Additional file 5.docx
Additional file 2.docx
Additional file 3.docx
Additional file 1.docx
Additional file 6. AMSTAR 2.docx
Additional file 8. PRISMA checklist.doc
Additional file 4.docx